>>Description of the research protocol "CQAWO39 A2315"

A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Immuno-allergologie
Brugmann identifier : CQAWO39 A2315
EudraCT identifier : 2016-001560-11


Involved department : Immuno-allergology
Principal investigator : Michel
Sponsor : novartis
Contact : Clinical Research Unit

>This protocol was approved by the St Pierre ethics committee.